These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8538222)

  • 1. Methotrexate for refractory Crohn's disease: preliminary answers to definitive questions.
    Kozarek RA
    Mayo Clin Proc; 1996 Jan; 71(1):104-5. PubMed ID: 8538222
    [No Abstract]   [Full Text] [Related]  

  • 2. Methotrexate treatment for Crohn's disease.
    Feagan BG
    Inflamm Bowel Dis; 1998 May; 4(2):120-1. PubMed ID: 9687221
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment.
    Parker R; Dixit A; Fraser A; Creed TJ; Probert CS
    Postgrad Med J; 2010 Apr; 86(1014):208-11. PubMed ID: 20354043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of methotrexate in patients with inflammatory bowel diseases.
    Preiss JC; Zeitz M
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S151-5. PubMed ID: 21044450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis.
    Calderón R; Estrada S; Ramírez de la Piscina P; Salvador M; Zabaleta S; Enciso C; Delgado E; García-Campos F
    Rev Esp Enferm Dig; 2010 Feb; 102(2):145-6. PubMed ID: 20361852
    [No Abstract]   [Full Text] [Related]  

  • 7. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
    Charpignon C; Beau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?].
    Lanyi B; Dienes HP; Kruis W
    Dtsch Med Wochenschr; 2005 Aug; 130(34-35):1944-7. PubMed ID: 16123897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate: the best choice for second-line maintenance treatment in active Crohn's disease?
    Grimaldi C
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):21-2. PubMed ID: 18977624
    [No Abstract]   [Full Text] [Related]  

  • 11. Is there a role for multidrug therapy in active Crohn's disease?
    Forbes A
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S257-8. PubMed ID: 18816649
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety profile of methotrexate in inflammatory bowel disease.
    Gabbani T; Deiana S; Lunardi S; Manetti N; Annese V
    Expert Opin Drug Saf; 2016 Oct; 15(10):1427-37. PubMed ID: 27462711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and tolerability of methotrexate for treating patients with Crohn's disease.
    Chande N; Abdelgadir I; Gregor J
    J Clin Gastroenterol; 2011 Aug; 45(7):599-601. PubMed ID: 21224737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?
    Burakoff R
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S202-3. PubMed ID: 18816760
    [No Abstract]   [Full Text] [Related]  

  • 16. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG; Rochon J; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Gillies R; Hopkins M
    N Engl J Med; 1995 Feb; 332(5):292-7. PubMed ID: 7816064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate dose in current ECCO consensus on Crohn's disease.
    Karaca C
    J Crohns Colitis; 2010 Oct; 4(4):483. PubMed ID: 21122548
    [No Abstract]   [Full Text] [Related]  

  • 18. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial.
    Arora S; Katkov W; Cooley J; Kemp JA; Johnston DE; Schapiro RH; Podolsky D
    Hepatogastroenterology; 1999; 46(27):1724-9. PubMed ID: 10430331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
    Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA; McDonald JW; Feagan BG
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003459. PubMed ID: 15674908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.